ReThink Medical, a San Francisco, CA-based data-driven heart failure medical device and digital health company, raised $3m in Series A funding.
The round, which added to the two National Institutes of Health (NIH) grants and a strategic partnership with Japanese medical device company Terumo Corporation, was led by medical device equity firm Emergent Medical Partners (EMP) with participation from Norwich Ventures and Launch Capital. In conjunction with the investment, Bob Brownell, managing director at EMP, will join ReThink Medical’s board of directors.
The company intends to use the funds for clinical trials and for further investment in its proprietary technology platform.
Founded in 2010 and led by Reza Naima, CEO, ReThink Medical uses predictive physiologic data to prevent hospitalizations for heart failure patients. By monitoring and analyzing data from patients in an ambulatory setting, the company’s proprietary algorithms can predict worsening conditions and alert physicians to take data-driven proactive measures for their patients.